Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Equity Average (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Equity Average data on record, last reported at $86.7 million in Q4 2025.

  • For Q4 2025, Equity Average fell 10.64% year-over-year to $86.7 million; the TTM value through Dec 2025 reached $86.7 million, down 10.64%, while the annual FY2025 figure was $97.8 million, 22.8% up from the prior year.
  • Equity Average reached $86.7 million in Q4 2025 per PLSE's latest filing, down from $98.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $116.7 million in Q1 2025 and bottomed at -$6.5 million in Q1 2023.
  • Average Equity Average over 5 years is $49.6 million, with a median of $43.1 million recorded in 2021.
  • The widest YoY moves for Equity Average: up 2348.74% in 2023, down 119.82% in 2023.
  • A 5-year view of Equity Average shows it stood at $45.9 million in 2021, then crashed by 95.7% to $2.0 million in 2022, then surged by 2348.74% to $48.3 million in 2023, then skyrocketed by 101.02% to $97.0 million in 2024, then fell by 10.64% to $86.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $86.7 million in Q4 2025, $98.6 million in Q3 2025, and $111.5 million in Q2 2025.